AstraZeneca's headquarters, where work is under way to catch up to obesity-drug market frontrunners Novo Nordisk and Eli ...

Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...

Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Indianapolis-based pharmaceutical giant Eli Lilly and Company has purchased 30.9 acres of vacant land to the north and to the ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...

Year-over-year BioSpace data shows there are fewer job postings live on the website and far more competition for them.

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...

AbCellera Forward-looking Statements. This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Secur ...

It seems like every day a new study emerges linking Ozempic and similar drugs to new health benefits. Ozempic is part of a drug class known as GLP-1 medications, which mimic gut hormones that help ...

Abcellera Biologics, Inc. ( (ABCL) ) has released its Q3 earnings. Here is a breakdown of the information Abcellera Biologics, Inc. presented ...

Despite a widened net loss, AbCellera Biologics Inc (ABCL) strengthens its pipeline and partnerships, maintaining robust ...